Page 11 - Sanket Koul

Surge in non-NCR regions pushes 19% rise in new project registration in UP

Uttar Pradesh saw a 19% rise in real estate project registrations in 2025, with non-NCR cities driving more balanced growth, UP Rera data showed

Budget 2026-27: Health sector seeks tax relief, rationalised rates

Ahead of Budget 2026-27, healthcare, medtech and pharma firms seek tax relief, higher R&D incentives and stronger support for preventive care and domestic manufacturing

GLP-1 launches inject over 2x rise in weight-loss market sales in 2025

Experts say OAds, insulin to dominate anti-diabetes market, with semaglutide patent loss leading to possible price erosion, value moderation

HC seeks Novo's response on Natco Pharma plea to revoke semaglutide patent

The patent in question is due to lapse in March next year. The court is scheduled to take up Natco's challenge for further hearing in February

NITI Aayog proposes Hudco & NHB-anchored fund for affordable rental housing

10-15% EWS/LIG reservation in all housing projects proposed, along with tax exemption for developer profits on affordable housing

DoP invites proposals under two schemes to cut medtech import reliance

With India importing about 70 per cent of its medical devices, the Department of Pharmaceuticals has invited proposals under two sub-schemes to reduce import dependence and support clinical studies

Govt bans sale, use of oral formulations of nimesulide for human use

The Union Health Ministry has prohibited manufacture and sale of oral nimesulide formulations above 100 mg for human use, citing liver toxicity risks and acting on ICMR and DTAB recommendations

Centre to restrict cough syrup sales by unlicensed village pharmacists

Draft amendments propose removing "syrup" from Schedule K exemptions, tightening over-the-counter sales in small villages after Madhya Pradesh cough syrup deaths

Intas, IntegriMedical sign pact to launch needle-free IVF injectors

Intas has signed an exclusive agreement with SII-backed IntegriMedical to deploy needle-free injection systems across IVF clinics, targeting an all-India rollout by Q1FY26.

Strong demand, premium pricing brings non- NCR developers to Gurugram

Industry experts agree that Gurugram's position as the corporate and commercial hub of NCR is a key draw

Health ministry unlikely to extend Schedule M GMP deadline for MSME pharma

The health ministry is unlikely to extend the revised Schedule M GMP deadline for MSME drugmakers beyond December 31, 2025, as it consults states ahead of risk-based inspections

Gaurs Group raises ₹440 crore via NCDs to fund realty, expansion plans

Delhi NCR-based Gaurs Group raised Rs 440 crore via NCDs subscribed by three mutual funds to fund land acquisition, project execution and refinancing, with debentures to list on NSE

Fake rabies vaccine row: IIL says counterfeit batch no longer available

Indian Immunologicals Limited said the issue flagged by Australian authorities relates to a single counterfeit batch identified earlier and does not warrant a blanket warning against the vaccine

Just 1 in 4 MSME pharma units set for GMP transition as deadline nears

Firms not complying with norms risk shutdowns once inspections begin next year

Housing sales slip to 17-quarter low in Q4 2025; launches fall 10%

Housing sales in the top nine cities fell 16% year on year to 98,019 units in Q4 2025, while new launches declined 10%; developers call it a phase of market realignment

Ajanta Pharma signs pact with Biocon to sell semaglutide in 26 countries

Ajanta Pharma has signed an in-licensing pact with Biocon to market semaglutide across 26 countries in Africa, the Middle East and Central Asia, subject to approvals

Education Ministry may consider expanding ONOS scheme to pvt universities

The Union Education Ministry is considering extending the One Nation One Subscription scheme to private higher education institutions, following representations from the private education sector

Bharat Biotech inks tech transfer pact with Biofabri for MTBVAC TB vaccine

Bharat Biotech has signed a technology transfer agreement with Spain's Biofabri to enable end-to-end manufacturing of MTBVAC, with a Phase 3 study in India expected to start recruitment in Q1 2026

Near-term impact on Indian drugmakers unlikely from US pricing policy

Analysts say the US move to link drug prices to the lowest global benchmarks targets patented medicines, limiting near-term risks for India's largely generic-focused exporters

Fortis acquires 125-bed People Tree Hospital in Bengaluru for ₹430 crore

Healthcare chain to invest Rs 840 crore to expand the facility's capacity to 300 beds, eyes over 1500 beds in the city by 2028